DMRA
Damora TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The bull case is that Damora now has a well-funded post-merger platform, stated cash of $257.6 million at December 31, 2025, runway said to extend into Phase 3 development of DMR-001, and a clear mid-2026 IND/CTA target for the lead mutCALR program, leaving room for a sharp rerating if execution stays on schedule [#10-K-2026-03-19].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +3.8.
What can break
Cash runway could shorten if development pace or operating spend rises faster than planned
Momentum
95
Value
41
Sentiment
20
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $38.00 · Bear $14.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $43.38
Why
Momentum95 · Δ7d +3.8
Value41 · Δ7d +0.0
Sentiment20 · Δ7d -10.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
95
26% active weight
Current posture
7d trendFlat
Δ7d
+3.8
Δ21d
+64.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
20
34% active weight
Current posture
7d trendSoftening
Δ7d
-10.6
Δ21d
-19.9
Why this grade
Composite grade D. Momentum 94.5 / Value 41.1 / Sentiment 19.9
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$2.03B
Beta
1.43
Shares Out
61.57M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.41
Rev YoY
-
EPS YoY
-57.8%
Gross Margin
-
Op Margin
-
Net Debt
-$256.21M
Current Ratio
22.48
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology